IQVIA艾昆纬：欧洲制药行业患者等待时间指标2025年调查报告（英文版）

However, the relevance of whether an innovative molecule is included on public reimbursement lists has diminished over the years, with a rise in patient access through alternative channels and/or with restrictions. This year’s iteration of the report retains the core availability metrics, whilst adding additional context around the positioning of the report within the broader access landscape, and greater granularity on the level of restrictions to patient access (i.e. individual patient only